- Home
- NVNI vs FULC Comparison
NVNI vs FULC Comparison
Compare NVNI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- FULC
- Stock Information
- Founded
- NVNI 2019
- FULC 2015
- Country
- NVNI Brazil
- FULC United States
- Employees
- NVNI N/A
- FULC N/A
- Industry
- NVNI
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- FULC Health Care
- Exchange
- NVNI Nasdaq
- FULC Nasdaq
- Market Cap
- NVNI 204.8M
- FULC 213.6M
- IPO Year
- NVNI N/A
- FULC 2019
- Fundamental
- Price
- NVNI $6.12
- FULC $3.82
- Analyst Decision
- NVNI
- FULC Hold
- Analyst Count
- NVNI 0
- FULC 9
- Target Price
- NVNI N/A
- FULC $7.63
- AVG Volume (30 Days)
- NVNI 22.8M
- FULC 515.1K
- Earning Date
- NVNI 02-11-2025
- FULC 02-25-2025
- Dividend Yield
- NVNI N/A
- FULC N/A
- EPS Growth
- NVNI N/A
- FULC N/A
- EPS
- NVNI N/A
- FULC N/A
- Revenue
- NVNI $23,558,620.00
- FULC $80,871,000.00
- Revenue This Year
- NVNI $25.91
- FULC $2,823.78
- Revenue Next Year
- NVNI $17.52
- FULC N/A
- P/E Ratio
- NVNI N/A
- FULC N/A
- Revenue Growth
- NVNI 38.59
- FULC 2987.86
- 52 Week Low
- NVNI $0.33
- FULC $2.86
- 52 Week High
- NVNI $12.19
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- NVNI 74.08
- FULC 39.01
- Support Level
- NVNI $4.57
- FULC $3.86
- Resistance Level
- NVNI $7.45
- FULC $4.24
- Average True Range (ATR)
- NVNI 1.18
- FULC 0.21
- MACD
- NVNI 0.45
- FULC -0.05
- Stochastic Oscillator
- NVNI 88.08
- FULC 22.90
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.